Logo image of AFMD

AFFIMED NV (AFMD) Stock Fundamental Analysis

USA - NASDAQ:AFMD - NL0015001ZQ0 - Common Stock

0.1815 USD
-0.1 (-34.95%)
Last: 5/19/2025, 8:00:00 PM
0.1731 USD
-0.01 (-4.63%)
After Hours: 5/19/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AFMD. AFMD was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of AFMD have multiple concerns. While showing a medium growth rate, AFMD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AFMD had negative earnings in the past year.
AFMD had a negative operating cash flow in the past year.
In the past 5 years AFMD always reported negative net income.
AFMD had a negative operating cash flow in each of the past 5 years.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -175.10%, AFMD is doing worse than 87.32% of the companies in the same industry.
AFMD has a Return On Equity of -406.92%. This is in the lower half of the industry: AFMD underperforms 75.89% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

AFMD has a Gross Margin of 789.74%. This is amongst the best in the industry. AFMD outperforms 100.00% of its industry peers.
AFMD's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AFMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
AFMD has about the same amout of shares outstanding than it did 1 year ago.
AFMD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AFMD is higher compared to a year ago.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.35, we must say that AFMD is in the distress zone and has some risk of bankruptcy.
AFMD's Altman-Z score of -4.35 is in line compared to the rest of the industry. AFMD outperforms 44.64% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that AFMD is not too dependend on debt financing.
AFMD has a worse Debt to Equity ratio (0.35) than 73.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -4.35
ROIC/WACCN/A
WACC6.81%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
AFMD has a worse Current ratio (1.93) than 76.79% of its industry peers.
AFMD has a Quick Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
AFMD's Quick ratio of 1.93 is on the low side compared to the rest of the industry. AFMD is outperformed by 75.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.15% over the past year.
AFMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
The Revenue for AFMD have been decreasing by -19.00% on average. This is quite bad
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

Based on estimates for the next years, AFMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.18% on average per year.
Based on estimates for the next years, AFMD will show a very strong growth in Revenue. The Revenue will grow by 35.57% on average per year.
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AFMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

AFMD's earnings are expected to grow with 19.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y19.02%

More info and screens

0

5. Dividend

5.1 Amount

AFMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFIMED NV

NASDAQ:AFMD (5/19/2025, 8:00:00 PM)

After market: 0.1731 -0.01 (-4.63%)

0.1815

-0.1 (-34.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2025-05-02/amc
Earnings (Next)06-09 2025-06-09
Inst Owners22.64%
Inst Owner Change-98.95%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap2.76M
Revenue(TTM)877.00K
Net Income(TTM)-69.97M
Analysts84
Price Target12.24 (6643.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)0%
PT rev (3m)-11.76%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-5.91%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-83.93%
Revenue NQ rev (3m)-83.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-5.18
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-5.77
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS0.07
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -4.35
F-Score1
WACC6.81%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A

AFFIMED NV / AFMD FAQ

What is the fundamental rating for AFMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to AFMD.


Can you provide the valuation status for AFFIMED NV?

ChartMill assigns a valuation rating of 0 / 10 to AFFIMED NV (AFMD). This can be considered as Overvalued.


How profitable is AFFIMED NV (AFMD) stock?

AFFIMED NV (AFMD) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AFMD stock?

The Earnings per Share (EPS) of AFFIMED NV (AFMD) is expected to grow by 40.97% in the next year.